Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children: Rationale and Progress to Date
Paediatr Drugs. 2023 Nov 30. doi: 10.1007/s40272-023-00606-6. Online ahead of print.ABSTRACTRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in children, and is associated with long-term pulmonary sequelae for up to 30 years after infection. The mainstay of RSV management is supportive therapy such as supplemental oxygen. Palivizumab (Synagis™-AstraZeneca), a monoclonal antibody targeting the RSV F protein site II, has been licensed for the prevention of RSV in high-risk groups since 1998. There has been recent promising progress in preventative strategies that includ...
Source: Paediatric Drugs - November 30, 2023 Category: Pediatrics Authors: Charl Verwey Ziyaad Dangor Shabir A Madhi Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Cantharidin Topical Solution 0.7%: First Approval
This article summarizes the milestones in the development of cantharidin 0.7% topical solution leading to this first approval for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older.PMID:38007409 | DOI:10.1007/s40272-023-00600-y (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 25, 2023 Category: Pediatrics Authors: Susan J Keam Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
Prophylactic Intravenous Acetaminophen in Extremely Premature Infants: Minimum Effective Dose Research by Bayesian Approach
CONCLUSIONS: Minimum effective dose to close the ductus was 25 mg/kg loading dose then 10 mg/kg/6 h for 5 days in extremely preterm infants. Acetaminophen was well tolerated in this study following these doses.TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04459117.PMID:37978159 | DOI:10.1007/s40272-023-00602-w (Source: Paediatric Drugs)
Source: Paediatric Drugs - November 17, 2023 Category: Pediatrics Authors: Na ïm Bouazza Gilles Cambonie Cyril Flamant Aline Rideau Manon Tauzin Juliana Patkai G éraldine Gascoin Mirka Lumia Outi Aikio Gabrielle Lui L éo Froelicher Bournaud Aisling Walsh-Papageorgiou Marine Tortigue Alban-Elouen Baruteau Jaana Kallio Mikko Ha Source Type: research
